Congenital Fibrinogen Deficiency Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Congenital Fibrinogen Deficiency Market Overview

The Congenital Fibrinogen Deficiency (CFD) market size across the three major markets (3MM: the US, Germany, and Japan) was $673.33 million in 2021 and is expected to achieve a CAGR of more than 1% during 2021-2031. The anticipated launch of Biotest/Grifols’ BT-524 is anticipated to propel growth of the market in the coming years. BT-524 is expected to launch in 2024 in Germany, 2025 in the US, and 2027 in Japan.

The CFD market research report provides an analysis of the key dynamics of the CFD drugs market. The report also offers insights into the key industry drivers and challenges. It also covers deals and R&D strategies in detail to highlight potential business opportunities.

The 3MM CFD Market Overview

The 3MM CFD Market Overview

To gain more information on the CFD market forecast, download a free report sample

CFD Market Drivers

The launch of two improved HFC products during the forecast period (BT-524 and FIB Grifols) will drive an increase in the overall market size of CFD across the 3MM. In addition, the steady increase in population will lead to a higher number of prevalent cases of CFD, resulting in higher rates of diagnosis, treatment, and increased awareness.

CFD Market Unmet Needs and Opportunities

CFD is an extremely rare disease with a small drug-treated patient population; this may discourage companies from investing in the space due to low sales potential. However, there is a need for new and differentiated therapeutic options, improved clinical trial designs, increased physician awareness of CFD symptomatology, and improved patient access and reimbursement for treatment.

Pharmaceutical companies have a large opportunity to develop safer drug options not manufactured from human plasma, and potentially curative gene therapies that target the underlying cause of CFD. Gene therapy holds the potential to dramatically change the way CFD is treated, based on the ability to correct the genetic mutation, and ideally eliminate the need for frequent IV infusions with HFCs.

CFD Market Segmentation by Approved Products

The key approved products in the CFD market are RiaSTAP, Fibryga, FibCLOT, and Fibrinogen HT. During the 2021 base year, RiaSTAP owned the largest market share.

CFD Market Analysis, by Approved Products

CFD Market Analysis, by Approved ProductsFor more insights on approved products in the CFD market, download a free report sample

CFD Market - Competitive Landscape

Some of the leading players in the CFD market are Biotest and Grifols. Both of them are working on blood derivative therapeutic classes of drugs.

CFD Market Report Overview

Market Size (2021 in 3MM) $673.33 million
CAGR (2021 – 2031) >1%
Key Approved Products RiaSTAP, Fibryga, FibCLOT, and Fibrinogen HT
Leading Players Biotest and Grifols

Scope

This report provides

  • Overview of CFD its pathogenicity, manifestations, and types of infection.
  • Epidemiology looks into the diagnosed incident and prevalent cases of CFD by sex and by 3MM.
  • Overview of diagnostics and treatment, treatment profiles of combination therapy for different CFD strains.
  • Quotes from three key opinion leaders (KOLs) from the 3MM.
  • Key topics covered for CFD drugs in the 3MM include trends, pipeline and market analysis, opportunities, challenges, and unmet needs.
  • Pipeline assessment: emerging novel trends under development, and analysis of the most promising late-stage CFD pipeline drugs in clinical development.
  • Analysis of the key dynamics of the CFD drugs market. Insightful review of the key industry drivers and challenges.
  • Deals and R&D strategies are covered in detail to highlight potential business opportunities.

Reasons to Buy

The report will help to understand:

  • What impact will late-stage pipeline agents have on the market? Which class of CFD drugs will have the highest peak sales, and why?
  • What country in the 3MM will experience the most growth, and why?
  • What are the current unmet needs and which pipeline drug or strategies are positioned to counter these unmet needs? What are the opportunities for R&D in the CFD space?
  • How is the field of CFD therapies going to move forward?
  • What is the current and future outlook for CFD therapeutics according to KOLs?

CSL Behring
Octapharma
LFB Group
Japan Blood Products Organization
Biotest
Grifols

Table of Contents

1 Executive Summary

1.1 Executive Summary

2 Disease Overview

2.1 Overview of Congenital Fibrinogen Deficiency (CFD)

2.2 Classification of CFD

2.3 Pathophysiology of CFD

2.4 Overview of Acquired Fibrinogen Deficiency (AFD)

2.5 Classification of AFD

2.6 CFD SWOT Analysis

3 Epidemiology

3.1 Diagnosed Prevalent Cases of CFD, Both Sexes, All Ages, 2021—2031

3.2 Diagnosed Prevalent Cases of CFD by Subtype, Both Sexes, All Ages, 2021

3.3 Sources and Methodology for Diagnosed Prevalent Cases of CFD

4 Current Treatment Options

4.1 Treatment Paradigm

4.2 Marketed Products

4.3 Product Profiles: RiaSTAP, Fibryga, FibCLOT, Fibrinogen HT

5 Unmet Needs and Opportunities

5.1 Unmet Needs in CFD

5.2 New and Differentiated Therapeutic Options

5.3 Improved Clinical Trial Designs

5.4 Increased Physician Awareness of CFD Symptomatology

5.5 Improved Patient Access and Reimbursement for Treatment

6 R&D Strategies

6.1 Trends in Clinical Trial Design in CFD

6.2 Trends in Deal-Making in CFD

7 Pipeline Assessment

7.1 CFD Pipeline Overview

7.2 Leading Pipeline Agents

7.3 Product Profiles: BT-524 and FIB Grifols

7.4 CFD: Clinical Trials (Phase II/III) Overview

8 Market Outlook

8.1 CFD Sales Forecast

8.2 CFD Market Forecast

8.3 Market Drivers and Barriers

9 Appendix

9.1 Primary Research: KOL Information

9.2 About the Authors

10 Contact Us

Frequently asked questions

Congenital Fibrinogen Deficiency Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 thematic reports
Currency USD
$6,995

Can be used by individual purchaser only

$20,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Congenital Fibrinogen Deficiency Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Congenital Fibrinogen Deficiency Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 in real time.

  • Access a live Congenital Fibrinogen Deficiency Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.